Clinical Trial Update: TAXUS ARRIVE: TAXUS Peri-Approval Registry: A Multi-Center Safety Surveillance Program [Phase 4]

View source ↗

Summary

Phase 4 safety surveillance registry evaluating the TAXUS paclitaxel-eluting stent in coronary artery disease has completed. The program was a multi-center effo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• TAXUS (paclitaxel-eluting stent)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Coronary Artery Disease | Phase 4 | Status: COMPLETED